The cost of a significant number of medicines that were not selected by the Ministry of Health for price reduction has increased - in some cases up to 30%. This is happening against the background of the introduction of the Cabinet of Ministers Resolution No. 168 and the publication by the Ministry of Health of lists of the most popular domestic drugs with reduced prices. Thus, a part of the pharmaceutical market remains destabilized, writes UNN.
Details
As of April 2025, the Ministry of Health has prepared two lists of domestic medicines, the prices of which should be reduced. The first includes 101 drugs and an average price reduction of 25%, although 30% was announced. The second contains 205 drugs with price reductions within 17%.
According to the People's Deputy, member of the Verkhovna Rada Committee on National Health, Medical Assistance and Medical Insurance Olga Stefanyshyna, there are currently about 20,000 medicines on the pharmaceutical market of Ukraine. That is, 306 drugs that the Ministry of Health makes more accessible constitute only about 1.5% of the market. Instead, the rest of the medicines that were not included in the TOP-100 lists are at risk of price increases.
For example, according to monitoring data, the cost of such drugs as "Valavir", "Betaspan", "Urolesan", "Darsil" and others shows a steady increase from January to April 2025.
In particular, the antiviral drug "Valavir" has increased in price by UAH 75.41, from UAH 933.69 to UAH 1009.1, and "Urolesan" capsules have increased in price by UAH 37, and "Betaspan" injection solution - by UAH 30, for "Darsil" tablets instead of UAH 280, you will now have to pay UAH 316, that is, UAH 36 more.
In the example of the analyzed drugs, the average price increase was about 13.5%, which indicates a general trend towards higher prices for drugs that are not included in the TOP-100. For some items, the increase reaches 20-30%.
This dynamic is a cause for concern, because many of the noted drugs are necessary for daily or course treatment of patients. If the prices of drugs outside the TOP lists of the Ministry of Health continue to rise, this will create an increasing financial burden on the wallets of Ukrainians in the context of war and economic instability, especially for patients with chronic diseases.
Let us remind you
Resolution of the Cabinet of Ministers of Ukraine No. 168 of February 14, 2025 provides new rules for regulating the pharmaceutical market. In particular, restrictions were introduced on markups on supply and distribution and retail allowances for all medicines, and not only for certain categories. In addition, the resolution prohibits retailers from entering into marketing agreements with pharmaceutical manufacturers, which allowed pharmacies to offer discounts to patients, implement social projects and conduct training for pharmacists.
The purpose of the resolution was to reduce the prices of medicines and increase their availability to the population. At the same time, patient organizations warned that excessive regulation could lead to drug shortages, the closure of pharmacies in small towns and villages, as well as the termination of social programs to support patients.
As reported by UNN in the State Regulatory Service, despite the fact that this CMU resolution is regulatory, it did not undergo their expertise. They emphasized that this is a violation of the Law on Regulatory Policy. The Ministry of Justice and the Commissioner of the Verkhovna Rada for Human Rights also did not provide their conclusions to the draft resolution. In particular, Ombudsman Dmytro Lubinets appealed to the Ministry of Health and the regulatory service due to the risks of closing pharmacies in villages and small towns.
• 5737 переглядiв
• 8204 переглядiв
• 10049 переглядiв
• 7479 переглядiв